GALILEO LIFE SCIENCES, INC. (OTCMKTS:MDRM) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal YearITEM 5.03 AMENDMENT TO ARTICLES OF INCORPORATION OR BYLAWS; CHANGES IN FISCAL YEAR
Effective December 12, 2014, the Board of Directors of then Modern Mobility Aids, Inc., a Nevada corporation (the “Company”), to unanimous written consent board of director resolutions, authorized a change in the Company’s name to Galileo Life Sciences, Inc. (the “Name Change”). On December 12, 2014, the Company filed a Certificate of Amendment with the Nevada Secretary of State amending its articles of incorporation to reflect the change in corporate name to “Galileo Life Sciences Inc.” (the “Amendment). The Amendment was approved by the Board of Directors to written consent resolutions dated December 12, 2014 and further approved by the shareholders holding a majority of the total issued and outstanding shares of common stock of the Company to written consent resolutions dated December 12, 2014.
SECTION 9 – FINANCIAL STATEMENTS AND EXHIBITS
Item 9.01
Financial Statements and Exhibits
(a) Financial Statements of Business Acquired.
Not applicable.
(b) Pro forma Financial Information.
Not applicable.
(c) Shell Company Transaction.
Not applicable.
(d) Exhibits.
Galileo Life Sciences, Inc. ExhibitEX-3.1.1 2 exhibit_3-1.htm CERTIFICATE OF AMENDMENT TO THE ARTICLES OF INCORPORATION DATED DECEMBER 12,…To view the full exhibit click here
About GALILEO LIFE SCIENCES, INC. (OTCMKTS:MDRM)
Galileo Life Sciences, Inc. is focused on the life sciences and healthcare industry. The Company is focused on acquiring companies within the biopharmaceutical sector, to focus research and development, and to create a manufacturing capacity in the three segments, which include contract research and manufacturing for life sciences companies, drug and device delivery format packaging and strategic development and production alliances. The Company plans to acquire or invest in multiple licensed producers in Canada and the United States. The Company is focused on exploiting the opportunities presented in the medical marijuana arena. The Company’s subsidiary is MDRM Group (Canada) Ltd. The Company also focuses on investing in licensed producers in Canada and the United States, as well as suppliers to the industry. As of March 31, 2015, the Company had not generated any revenues and had not commenced any revenue generating activities.